Antibody Drug Conjugates Market Overview: Market Size, Drivers And Trends
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032
North America held the largest antibody drug conjugates market share, and Middle East was the fastest-growing region in 2022.
The global antibody drug conjugates market is expected to grow from $5.9 billion in 2022 to $7.2 billion in 2023 at a compound annual growth rate (CAGR) of 22.1%. The antibody drug conjugates market is expected to grow from $16.15 billion in 2027 at a CAGR of 22.4%.
Major Driver In The Antibody Drug Conjugates Market – Rise In The Incidences Of Cancer Globally
Obesity, smoking, drinking, and poor dietary habits are the leading causes of most malignancies. Cancer Research UK projects that by 2040, there will be 27.5 million new instances of cancer every year. Rising cancer occurrences are likely to drive demand for antibody-drug conjugates, propelling the market forward.
View More On The Antibody Drug Conjugates Market Report 2023 – https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report
Key Antibody Drug Conjugates Market Segments
1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types
2) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications
3) By Product: Adcertis, Kadcyla, Other Products
4) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology
5) By End User: Hospital, Clinics, Other End Users
Recent Antibody Drug Conjugates Market Trend – Strategic Collaborations
Manufacturers of antibody-drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, in March 2022, Sanofi, a France-based multinational pharmaceutical and healthcare company, collaborated with a US-based biotechnology company, Seagen Inc., to create up to three cancer targets for antibody-drug conjugates (ADCs), develop them, and market them.
Antibody Drug Conjugates Market Prominent Players
Major players in the antibody drug conjugates market are Bayer AG, Concortis Biotherapeutics, F. Hoffmann-La Roche Ltd., Immunomedics Inc., Oxford BioTherapeutics, Pfizer Inc., Seattle Genetics Inc., Takeda Pharmaceutical Company Limited, Abbvie Inc., and Astellas Pharma/Agensys.
Request A Sample Of The Global Antibody Drug Conjugates Market Report 2023:
The Antibody Drug Conjugates Global Market Report 2023 provides a comprehensive overview on the antibody drug conjugates market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
Antibody-drug conjugates (ADCs) are drugs designed specifically to deliver chemotherapy to cancer cells. ADCs work by connecting a linker to a monoclonal antibody that binds to a specific target expressed on cancer cells.A deadly chemical is released into the cancer cell as soon as the ADC binds to its target (a cancer protein or receptor).
Follow us on:
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model